REFERENCE GUIDE 01

TASMINH4 PATIENT ELIGIBILITY CRITERIA

For reference in completion of Eligibility Summary in baseline CRF

Inclusion Criteria

IC1. Participant is willing and able to give informed consent for participation in the trial
IC2. Male or Female, aged 35 years or above
IC3. On practice hypertension register, not already taking more than 3 anti-hypertensive agents and above clinic target BP (i.e. ≥140/90 mmHg) at baseline (mean of 2nd/3rd readings)
IC4. Stable dose of current antihypertensive medication for at least four weeks prior to trial entry
IC5. In the Investigator’s opinion, is able and willing to comply with all trial requirements or has a carer able to help sufficiently (e.g. in the case of physical issues with self-monitoring)
IC6. Willing to allow his or her GP to be notified of participation in the trial

Exclusion Criteria

EC1. BP below target at baseline (i.e. <140/90 mmHg on clinic measurement at baseline visit)
EC2. Already taking more than 3 anti-hypertensive agents please refer to RG02 for drugs list
EC3. Orthostatic hypotension: more than 20mmHg systolic drop after standing for 1 minute
EC4. Diagnosed atrial fibrillation
EC5. Unwilling to self-monitor
EC6. BP managed outside of primary care (including secondary hypertension)
EC7. Unable to provide consent
EC8. Dementia or score over 10 on the short orientation memory concentration test (and with no carer support)
EC9. Female participant who is pregnant, lactating or planning pregnancy during the course of the trial
EC10. The partner or spouse of an individual already randomised in the trial
EC11. Chronic Kidney Disease (CKD) Grade 4 or worse; any grade of CKD with proteinuria
EC12. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial (e.g. terminal illness, house bound and unable to attend baseline and follow up clinics)
EC13. Participants who have participated in another research trial involving an antihypertensive medication in the past 4 weeks